



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_53291
Title of the Manuscript:	NOVEL SPECTROPHOTOMETRIC METHODS FOR SIMULTANEOUS DETERMINATION OF ROSUVASTATIN CALCIUM, TIMOLOL MALEATE AND DICLOFENAC SODIUM IN PHARMACEUTICAL TERNARY MIXTURE AND SPIKED HUMAN PLASMA
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>The manuscript was informed application on spiked human plasma but no figures, tables or graphs were mentioned.</p> <p>Table 1 provides information about repeatability and Interday precision which is the same meaning as the author mention on the paragraph but with different values</p> <p>Table 2 provides information about recoveries in the presence of excipients (the authors must mention the compounds were used as excipients</p> <p>In introduction the chemical form of ROSCa.not contain Ca. also the chemical structure of ROSCa was writen wronge H₅₄ not H₄₅ .</p> <p>In 4.1. APPLYING THE 1STDD METHOD FOR THE TERNARY MIXTURE Line 14 The value 253.5 nm of DICNa is not correct according to figure6 (b).</p> <p>In table 3. TheT test and F values are not correct (must be reviewed by the authors.</p>	
Minor REVISION comments	<p>In introduction:The authors must mention the physical characters of TIM &DICNa as ROSCa.</p> <p>In introduction:The authors must mention the chemical structure of TIM &DICNa as ROSCa.</p> <p>In Abstract :the authors mention the LOD of ROSCa determined by the first method and not mention the other products and other techiques.the part which discuss the first method must be modified.</p>	
Optional/General comments	<p>The titles of the manuscript must be <u>bold font</u></p> <p>In 2.1.1 pure standards Timilol maleate& diclofenac sodium must be abbreviated to TIM and DIC as there are written only in the first time mentioned .</p>	



[SDI Review Form 1.6](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	<i>Mohamed Abdelrady Korashy</i>
Department, University & Country	<i>Egypt</i>